Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m 2) in the treatment of gynecologic cancers

Gynecologic Oncology

Volumn 97, Issue 2, 2005, Pages 374-378

  Kim, Robert J ^a   Peterson, Gertrude ^a   Kulp, Barbara ^a   Zanotti, Kristine M ^a   Markman, Maurie ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Gynecologic cancer; Liposomal doxorubicin; Palmar plantar erythrodysesthesia; Skin toxicity

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; FAMOTIDINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLISTER; DESQUAMATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; ENDOMETRIUM CANCER; ERYTHEMA; FEMALE; GYNECOLOGIC CANCER; HUMAN; LOW DRUG DOSE; MEDICAL RECORD; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; SIDE EFFECT; SKIN EDEMA; SKIN INFECTION; SKIN MANIFESTATION; SKIN TOXICITY; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

EID: 18144392975     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.12.057     Document Type: Article

References (32)

1. Ovarian Cancer Meta Project: cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis J. Clin. Oncol. 9 1991 1668 1674
2. R.P. A'Hern, and M.E. Gore Impact of doxorubicin on survival in advanced ovarian cancer J. Clin. Oncol. 13 1995 726 732
3. J. Fanning, T.Z. Bennett, and R.D. Hilgers Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma Obstet. Gynecol. 80 1992 954 960
4. A. Gadducci, M. Bruzzone, F. Carnino, N. Ragni, A. Rubagotti, and P.F. Conte Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer Int. J. Gynecol. Cancer 6 1996 286 290
5. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
6. S.A. Cannistra Cancer of the ovary N. Engl. J. Med. 329 1993 1550 1559
7. B. Uziely, S. Jeffers, R. Isacson, K. Kutsch, D. Wei-Tsao, and Z. Yehoshua Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J. Clin. Oncol. 13 1995 1777 1785
8. S. Madhavan, and D.W. Northfelt Lack of vesicant injury following extravasation of liposomal doxorubicin J. Natl. Cancer Inst. 87 1995 1556 1557
9. R.F. Greene, J.M. Collins, J.F. Jenkins, J.L. Speyer, and C.E. Myers Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols Cancer Res. 43 1983 3417 3421
10. T.M. Allen Liposomes Drugs 54 Suppl 4 1997 8 14
11. M.C. Woodle, and D.D. Lasic Sterically stabilized liposomes Biochim. Biophys. Acta 1113 1992 171 199
12. F.M. Muggia, J.D. Hainsworth, S. Jeffers, P. Miller, S. Groshen, and M. Tan Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J. Clin. Oncol. 15 1997 987 993
13. M. Lotem, A. Hubert, O. Lyass, M.A. Goldenhersh, A. Ingber, and T. Peretz Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin Arch. Dermatol. 136 12 2000 1475 1480
14. 2) in platinum/paclitaxel refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum Gynecol. Oncol. 78 2000 369 372
15. S.M. Campos, R.T. Penson, A.R. Mays, R.S. Berkowitz, A.F. Fuller, and A. Goodman The clinical utility of liposomal doxorubicin in recurrent ovarian cancer Gynecol. Oncol. 81 2001 206 212
16. P.F. Escobar, M. Markman, K. Zanotti, K. Webster, and J. Belinson Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer J. Cancer Res. Clin. Oncol. 11 2003 651 654
17. G. Berry, M. Billingham, E. Aderman, P. Richardson, F. Torti, and B. Lum The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin Ann. Oncol. 9 1998 711 716
18. F.J. Martin Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology Oncology 11 Suppl 11 1997 11 20
19. F.J. Martin Stealth: liposome technology-An overview Doxil. Clin. Ser. 1 1996 1 8
20. A. Gabizon, D. Goren, and A. Horowitz Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals Adv. Drug Deliv. Rev. 24 1997 337 344
21. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, and R. Cohen Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res. 54 1994 987 992
22. J.E. Fitzpatrick The cutaneous histopathology of chemotherapeutic reactions J. Cutaneous Pathol. 20 1993 1 14
23. J.S. Patel Pyridoxine for hand-foot syndrome Hosp. Pharm. 34 1999 604 609
24. M. Mackean, A. Planting, C. Twelves, J. Schellens, D. Allman, and B. Osterwalder Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer J. Clin. Oncol. 16 1998 2977 2985
25. F.M. Muggia, J.A. Blessing, J. Sorosky, and G.C. Reid Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group Study J. Clin. Oncol. 9 2002 2360 2364
26. A.N. Gordon, C.O. Granai, P. Rose, J. Hainsworth, A. Lopez, and C. Weissman Phase II study of stealth liposomal doxorubicin (Doxil) in platinum and paclitaxel refractory epithelial ovarian cancer J. Clin. Oncol. 18 2000 3093 3100
27. A.N. Gordon, J.T. Fleagle, D. Guthri, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma; a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19 2001 3312 3322
28. P.G. Rose, J.H. Maxson, N. Fusco, K. Mossbruger, and M. Rodriguez Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages Gynecol. Oncol. 82 2001 323 328
29. D.M. Vail, R. Chun, D.H. Thamm, L.D. Garrett, A.J. Cooley, and J.E. Obradovich Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model Clin. Cancer Res. 4 1998 1567 1571
30. F.D. Malkinson, L. Geng, and W.R. Hanson Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin J. Invest. Dermatol. 101 1993 135 137 [Suppl]
31. A.M. Lopez, L. Wallace, R.T. Dorr, M. Koff, E.M. Hersh, and D.S. Alberts Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia Cancer Chemother. Pharmacol. 44 1999 303 306
32. Uyar D., Kulp B., Peterson G., Zanotti K., Markman M. Cardiac safety profile of prolonged (≥6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol. Oncol. (in press)